Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.60 |
| ▸ | CA1 | P00915 | 6/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.59 |
| ▸ | CA4 | P22748 | 3/20 | 0.59 |
| ▸ | CA7 | P43166 | 3/20 | 0.59 |
| ▸ | CA9 | Q16790 | 3/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355080 | 0.89 | PTGS2 (0.62) | PTGS2CA1CA2CA4CA7 | |
| SCHEMBL5206224 | 0.88 | PTGS2 (0.60) | PTGS2CA1CA2CA4CA7 | |
| SCHEMBL3359602 | 0.87 | CA1 (0.61) | PTGS2CA1CA2CA4CA7 | |
| SCHEMBL4028727 | 0.87 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL4248349 | 0.86 | PTGS2 (0.75) | PTGS2CA1CA2CA4CA7 | |
| SCHEMBL3352528 | 0.84 | PTGS2 (0.61) | PTGS2CA1CA2CA4CA7 | |
| SCHEMBL3355461 | 0.84 | CA2 (0.56) | PTGS2CA1CA2CA4CA9 | |
| SCHEMBL5204710 | 0.83 | PTGS2 (0.65) | PTGS2CA1CA2CA4CA7 | |
| SCHEMBL1382505 | 0.83 | PTGS2 (0.65) | PTGS2CA1CA2CA4CA7 | |
| SCHEMBL3356888 | 0.83 | PTGS2 (0.61) | PTGS2CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473700-B2 | 1,2,4-triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | CJ CORPORATION (KR) | 2009-01-06 | — | — | US | claimed |
| US-20060074118-A1 | 1, 2, 4 - Triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | CJ CORPORATION (JP) | 2006-04-06 | — | — | US | claimed |
| US-7473700-B2 | 1,2,4-triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | CJ CORPORATION (KR) | 2009-01-06 | — | — | US | disclosed |
| US-7473700-B2 | 1,2,4-triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | CJ CORPORATION (KR) | 2009-01-06 | — | — | US | disclosed |
| US-7473700-B2 | 1,2,4-triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | CJ CORPORATION (KR) | 2009-01-06 | — | — | US | disclosed |
| US-20060074118-A1 | 1, 2, 4 - Triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | CJ CORPORATION (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1565447-A4 | 1,2,4-TRIAZOLE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CJ CORP (KR) | 2005-11-16 | — | — | EP | disclosed |
| EP-1565447-A1 | 1,2,4-TRIAZOLE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CJ Corporation (KR) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048347-A1 | 1,2,4-TRIAZOLE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CJ CORPORATION (KR) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074118-A1 | 1, 2, 4 - Triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same | CYP4B1, CYP3A4, CYP3A5 | PTGS2 2356/4885CA1 2194/4885CA2 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.